DSM Pharmaceuticals Appoints Business Unit Director - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

DSM Pharmaceuticals Appoints Business Unit Director



DSM Pharmaceuticals has appointed Manja Bouman PhD as president and business unit director of its biopharm businesses at DSM Pharmaceutical Products. Bouman will head the DSM Biologics/BioSolutions businesses within the DSM Pharmaceutical Products business group of Royal DSM. Bouman will report to Lukas Utiger, president and CEO of DSM Pharmaceutical Products, as a member of the management team.

Bouman has a PhD in biochemistry from the State University of New York at Buffalo, School of Medicine & Biomedical Sciences and has held postdoctoral positions there and in Nijmegen, the Netherlands, before joining DSM Gist-Brocades in 1997. In that role, Bouman was responsible for new business development and licensing & technology moving to Kiadis Pharma B.V. as CEO in 2004. Bouman was most recently CEO of Regenesance, a company that focuses on the development of monoclonal antibodies that inhibit MAC formation for treatment of chronic and acute neurological disorders.

Bouman also heads DSM BioSolutions, which offers large-scale fermentation for large-and small-molecule API’s for therapeutic proteins and enzymes at DSM’s Capua, Italy site, with support from the DSM Biotechnology Center in Delft, the Netherlands.

Source: DSM Pharmaceuticals

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here